Massachusetts-based cell-centric life sciences company Cellarity has raised USD 121 million in a Series C funding round led by Flagship Pioneering with participation from Japanese biotech firm Kyowa Kirin and Hanwha Impact Partners.
The proceeds will be directed towards advancing its drug discovery pipeline towards the clinic, further developing its AI-powered computational platform, and growing its headcount.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.